{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:49:08Z","timestamp":1791244148378,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81902577"],"award-info":[{"award-number":["81902577"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Research Foundation for the Postdoctoral Program of Sichuan University","award":["2021SCU12014"],"award-info":[{"award-number":["2021SCU12014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intraductal carcinoma of the prostate (IDC-P) is a subtype of prostate cancer featured by poor prognosis. Previous studies suggested IDC-P could have a potentially unstable genome. Homologous recombination deficiency (HRD) score is a result-oriented method to describe the genomic instability status. This study investigates the association of HRD scores with IDC-P and other clinicopathological factors and the prognostic implication of HRD scores in an aggressive prostate cancer cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study involved 123 PCa patients, including high-risk localized (M0) and de novo metastatic (M1) diseases. HRD score is calculated based on over 10,000 single-nucleotide polymorphisms distributed across the human genome. We explored the association between HRD scores and clinicopathological characteristics, genomic alterations, and patients\u2019 prognoses using rank-sum tests, chi-square tests, Kaplan-Meier curves, and Cox proportional hazards method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median HRD score of this cohort is 21.0, with 65 (52.8%) patients showing HRD score\u226521. Tumors with IDC-P displayed higher HRD scores than adenocarcinoma (<jats:italic>P<\/jats:italic>=0.002); other high HRD score-related factors included M1 (<jats:italic>P<\/jats:italic> =0.008) and high ISUP grades (4\u20135) (<jats:italic>P<\/jats:italic>=0.001). <jats:italic>MYC<\/jats:italic> mutations were associated with high HRD scores (<jats:italic>P<\/jats:italic>&lt;0.001) in the total cohort. <jats:italic>TP53<\/jats:italic> mutations (<jats:italic>P<\/jats:italic>=0.010) and HRR pathway mutations (<jats:italic>P<\/jats:italic>=0.028) corresponded to high HRD scores in IDC-P positive and non-IDC-P patients, respectively, but not vice versa. HRD scores higher than 21 indicated significantly worse survival in the total cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>M1, high Gleason score, and IDC-P pathology represent higher HRD scores in PCa. Tumors with IDC-P might have different driven mechanisms for high HRD scores than non-IDC-P. HRD score displayed prognostic value in this aggressive prostate cancer cohort.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02430-0","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:02:41Z","timestamp":1658448161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)"],"prefix":"10.1186","volume":"20","author":[{"given":"Sha","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinge","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengnian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronggui","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"issue":"10","key":"2430_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020;19(10):711\u201336.","journal-title":"Nat Rev Drug Discov"},{"key":"2430_CR2","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163(4):1011\u201325.","DOI":"10.1016\/j.cell.2015.10.025"},{"issue":"5","key":"2430_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215\u201328.","journal-title":"Cell."},{"issue":"3","key":"2430_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41416-020-01114-x","volume":"124","author":"R Lozano","year":"2021","unstructured":"Lozano R, Castro E, Arag\u00f3n IM, Cend\u00f3n Y, Cattrini C, L\u00f3pez-Casas PP, et al. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer. 2021;124(3):552\u201363.","journal-title":"Br J Cancer"},{"issue":"1","key":"2430_CR5","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen L, WM Martens J, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11(1):5584.","journal-title":"Nat Commun"},{"issue":"4","key":"2430_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23(4):517\u201325.","journal-title":"Nat Med"},{"issue":"6","key":"2430_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","volume":"16","author":"KM Timms","year":"2014","unstructured":"Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, et al. Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16(6):475.","journal-title":"Breast Cancer Res"},{"key":"2430_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","volume":"3","author":"AM Marquard","year":"2015","unstructured":"Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015;3:9.","journal-title":"Biomark Res"},{"issue":"4","key":"2430_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.juro.2018.10.016","volume":"201","author":"J Zhao","year":"2019","unstructured":"Zhao J, Liu J, Sun G, Zhang M, Chen J, Shen P, et al. The prognostic value of the proportion and architectural patterns of intraductal carcinoma of the prostate in patients with de novo metastatic prostate cancer. J Urol. 2019;201(4):759\u201368.","journal-title":"J Urol"},{"issue":"5","key":"2430_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4103\/aja.aja_117_19","volume":"22","author":"S Zhu","year":"2020","unstructured":"Zhu S, Zhao JG, Chen JR, Liu ZH, Sun GX, Wang ZP, et al. Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer. Asian J Androl. 2020;22(5):519\u201325.","journal-title":"Asian J Androl"},{"issue":"3","key":"2430_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/pros.22906","volume":"75","author":"T Zhao","year":"2015","unstructured":"Zhao T, Liao B, Yao J, Liu J, Huang R, Shen P, et al. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer? Prostate. 2015;75(3):225\u201332.","journal-title":"Prostate."},{"key":"2430_CR12","doi-asserted-by":"crossref","unstructured":"Zhao J, Sun G, Zhu S, Dai J, Chen J, Zhang M, et al. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. BJU Int. 2022;129(3):345\u201355.","DOI":"10.1111\/bju.15530"},{"key":"2430_CR13","doi-asserted-by":"crossref","unstructured":"Lawrence MG, Porter LH, Clouston D, Murphy DG, Frydenberg M, Taylor RA, et al. Knowing what\u2019s growing: Why ductal and intraductal prostate cancer matter. Sci Transl Med. 2020;12(533):eaaz0152.","DOI":"10.1126\/scitranslmed.aaz0152"},{"issue":"4","key":"2430_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cell.2019.01.025","volume":"176","author":"S Chen","year":"2019","unstructured":"Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, et al. Widespread and functional RNA circularization in localized prostate cancer. Cell. 2019;176(4):831\u201343.e22.","journal-title":"Cell."},{"issue":"5","key":"2430_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/pros.23484","volume":"78","author":"P Isaacsson Velho","year":"2018","unstructured":"Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, et al. Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate. 2018;78(5):401\u20137.","journal-title":"Prostate."},{"issue":"Database issue","key":"2430_CR16","doi-asserted-by":"publisher","first-page":"D493","DOI":"10.1093\/nar\/gkh103","volume":"32","author":"D Karolchik","year":"2004","unstructured":"Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D, et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res. 2004;32(Database issue):D493\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"2430_CR17","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754\u201360.","journal-title":"Bioinformatics."},{"issue":"1","key":"2430_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13046-017-0591-4","volume":"36","author":"D Su","year":"2017","unstructured":"Su D, Zhang D, Chen K, Lu J, Wu J, Cao X, et al. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods. J Exp Clin Cancer Res. 2017;36(1):121.","journal-title":"J Exp Clin Cancer Res"},{"key":"2430_CR19","doi-asserted-by":"crossref","unstructured":"Huang K, Wang J, Yang B, Bai Y, Zhao X. Computing HRD score by a capture-based NGS panel reveal its prevalence in Chinese breast, ovarian, prostate and pancreatic cancer patients. Ann Oncol. 2020;31(4_suppl);S790.","DOI":"10.1016\/j.annonc.2020.08.100"},{"issue":"15_suppl","key":"2430_CR20","doi-asserted-by":"publisher","first-page":"e13051","DOI":"10.1200\/JCO.2021.39.15_suppl.e13051","volume":"39","author":"Y Chen","year":"2021","unstructured":"Chen Y, Cui L, Zhang B, Zhao X, Xu B. Efficacy of platinum-based chemotherapy in advanced triple-negative breast cancer in association with homologous recombination deficiency. J Clin Oncol. 2021;39(15_suppl):e13051\u2013e.","journal-title":"J Clin Oncol"},{"issue":"4 Supplement","key":"2430_CR21","first-page":"PS4","volume":"81","author":"X Wang","year":"2021","unstructured":"Wang X, Du F, Yue J, Si Y, Cui L, Yuan P. Abstract PS4-46: Homologous recombination deficiency score predicts patient characteristics and outcomes of triple negative breast cancer in China. Cancer Res. 2021;81(4 Supplement):PS4\u201346.","journal-title":"Cancer Res"},{"issue":"10","key":"2430_CR22","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776\u201382.","journal-title":"Br J Cancer"},{"issue":"4","key":"2430_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2(4):366\u201375.","journal-title":"Cancer Discov"},{"issue":"21","key":"2430_CR24","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","volume":"72","author":"T Popova","year":"2012","unstructured":"Popova T, Mani\u00e9 E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation. Cancer Res. 2012;72(21):5454\u201362.","journal-title":"Cancer Res"},{"issue":"21","key":"2430_CR25","doi-asserted-by":"publisher","first-page":"8748","DOI":"10.1158\/0008-5472.CAN-10-0944","volume":"70","author":"KR Luoto","year":"2010","unstructured":"Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, et al. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res. 2010;70(21):8748\u201359.","journal-title":"Cancer Res"},{"issue":"1","key":"2430_CR26","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1038\/s41467-019-10993-5","volume":"10","author":"JF Ning","year":"2019","unstructured":"Ning JF, Stanciu M, Humphrey MR, Gorham J, Wakimoto H, Nishihara R, et al. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nat Commun. 2019;10(1):2910.","journal-title":"Nat Commun"},{"key":"2430_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ebiom.2019.03.027","volume":"43","author":"J Yi","year":"2019","unstructured":"Yi J, Liu C, Tao Z, Wang M, Jia Y, Sang X, et al. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. EBioMedicine. 2019;43:225\u201337.","journal-title":"EBioMedicine."},{"issue":"3","key":"2430_CR28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/0008-5472.CAN-17-1494","volume":"78","author":"JPW Carey","year":"2018","unstructured":"Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, et al. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Res. 2018;78(3):742\u201357.","journal-title":"Cancer Res"},{"issue":"1","key":"2430_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23(1):239\u201354.e6.","journal-title":"Cell Rep"},{"issue":"5","key":"2430_CR30","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019;28(5):1370\u201384.e5.","journal-title":"Cell Rep"},{"issue":"6","key":"2430_CR31","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41379-020-00731-4","volume":"34","author":"TL Lotan","year":"2021","unstructured":"Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, et al. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Mod Pathol. 2021;34(6):1185\u201393.","journal-title":"Mod Pathol"},{"key":"2430_CR32","doi-asserted-by":"crossref","unstructured":"Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, et al. Utility of homologous recombination deficiency biomarkers across cancer types. JCO Precis. Oncol. 2022;6:e2200085","DOI":"10.1200\/PO.22.00085"},{"issue":"5","key":"2430_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.eururo.2017.04.034","volume":"72","author":"MLK Chua","year":"2017","unstructured":"Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, et al. A prostate cancer \u201cnimbosus\u201d: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies. Eur Urol. 2017;72(5):665\u201374.","journal-title":"Eur Urol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02430-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02430-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02430-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:03:00Z","timestamp":1658448180000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02430-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2430"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02430-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Protocols in this study obtained West China Hospital institutional review board approval (HX-IRB-2021-1703). All patients provided written consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This work does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}